WO2002030422A1 - Utilisation de substances definies se liant aux recepteurs sigma dans le traitement de sarcomes et de carcinomes - Google Patents

Utilisation de substances definies se liant aux recepteurs sigma dans le traitement de sarcomes et de carcinomes Download PDF

Info

Publication number
WO2002030422A1
WO2002030422A1 PCT/EP2001/011710 EP0111710W WO0230422A1 WO 2002030422 A1 WO2002030422 A1 WO 2002030422A1 EP 0111710 W EP0111710 W EP 0111710W WO 0230422 A1 WO0230422 A1 WO 0230422A1
Authority
WO
WIPO (PCT)
Prior art keywords
piperidyl
butyl
indole
benzyl
ethyl
Prior art date
Application number
PCT/EP2001/011710
Other languages
German (de)
English (en)
Inventor
Christoph Van Amsterdam
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Priority to AU2002210527A priority Critical patent/AU2002210527A1/en
Publication of WO2002030422A1 publication Critical patent/WO2002030422A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention relates to the use of substances known per se for the treatment of carcinomas and sarcomas.
  • the substances whose use is the subject of the invention bind with high affinity to both known sigma receptors ( ⁇ receptors).
  • the ⁇ receptors belong to the class of opioid receptors.
  • the first evidence of the existence of various opioid receptors came from Martin and co-workers who conducted experiments on dogs (J. Pharma Coll. Exp. Ther. 197: 517 to 532, 1976). Striking differences in the pharmacological behavior of various narcotic analgesics and their inability to replace each other with regard to withdrawal symptoms led Martin and co-workers to postulate the existence of three different types of receptors. These were named after the prototypical pharmaceuticals used ⁇ for morphine, K for ketocyclazocin and ⁇ for SKF 10047 (N-allylnormetazocin). After the discovery of the enkephalins, another group of receptors, the ⁇ receptors, was discovered.
  • the ⁇ -opioid receptors which are expressed in the central nervous system like the other opioid receptors, have properties that distinguish them from the other opioid receptors. For example, the effects of these receptors are not offset by naloxone. There is also an overlap between ⁇ binding sites and binding sites for non-opiates such as phencyclidine (angel dust). In the more recent literature, the ⁇ receptors are therefore not included in the opioid receptors.
  • ⁇ receptors There are two subtypes of ⁇ receptors, ⁇ i and ⁇ 2 [Quirion et al., Trends Pharmacol. Be. 13, 85, 1992; Walker et al. Aspects of synaptic transmission, editor TW Stone (Taylor and Francis, London) page 91, 1993; Bowen Aspects of synaptic transmission, editor TW Stone (Taylor and Francis, London), page 1 13, 1993].
  • ⁇ -receptors can be found in various peripheral tissues such as liver, kidney, gastrointestinal tract and endocrine glands such as ovaries, adrenal glands, testes and pituitary glands, as well as in leukocytes.
  • ⁇ -Receptor ligands are known to inhibit the growth of certain cancers, such as small cell lung cancer.
  • Various ⁇ -receptor ligands are already known:
  • IPAB (2-piperidinylaminoethyl) -4-iodobenzamide
  • ⁇ -receptor ligands are all compounds that bind to the ⁇ i-receptor and / or to the ⁇ -receptor with high affinity.
  • the affinity is the IC 50 value of the displacement of radioactively labeled SKF-10047 (in the case of the ⁇ i receptor) and of radioactive 1,3-di-o-tolylguanidine (DTG) (in the case of the ⁇ 2 - Receptor).
  • Tris-HCl (2-amino-2- (hydroxymethyl) -1, 3-propanediol hydrochloride), pH 7.7 is used as the incubation buffer;
  • Tris buffer Tris-HCl buffer, pH 7.7
  • Glass-Teflon homogenizer 10 bursts, 800 rpm
  • the homogenate is centrifuged for 15 minutes at 2 ° C at 20,000 rpm in a SS-34 rotor;
  • the pellet is resuspended in Tris buffer, a concentration of 10 mg of original tissue per ml being set, and frozen in aliquots at - 28 ° C; -
  • the suspension is thawed in a water bath at room temperature, washed twice in 50 ml of Tris buffer and then centrifuged at 22,000 g for 10 minutes;
  • the ICso value is determined in a volume of 0.5 ml with 0.5 nM 3 H-DTG and 4 mg original tissue per ml at 25 ° C
  • the invention further relates to the use of one of the above compounds or the corresponding pharmaceutically acceptable acids, bases or salts for the manufacture of a medicament for the treatment of carcinomas and sarcomas.
  • Another object of the invention is the use of one of the above substances for the treatment of small cell lung carcinomas, breast and colon carcinomas and melanomas.
  • the compounds used according to the invention are generally more or less basic. They can be converted into the associated acid addition salt using an acid, for example by reacting equivalent amounts of the base and the acid in an inert solvent such as ethanol and subsequent evaporation.
  • an inert solvent such as ethanol and subsequent evaporation.
  • acids that provide physiologically acceptable salts are suitable for this implementation.
  • So inorganic acids can be used, for example sulfuric acid, nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, and also organic acids, especially aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or polybasic carbon, sulfone - or sulfuric acids, for example formic acid, acetic acid, propionic acid, pivalic acid, diethyl acetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, methanoic acid or isonicotinic acid - thanesulfonic acid, p-toluenesulfonic acid, naphthalene mono- and disulfonic acids or laurylsulfuric acid.
  • the product obtained is the pharmaceutically acceptable salt of the corresponding base, which was listed above. If compounds to be used according to the invention react acidically in aqueous solution, these can be converted into the corresponding salt by adding basic compounds. If a compound listed above is a salt, the active compound can be released by adding acid or base or, if necessary, by simple hydrolysis. If the compounds are to be used as part of a pharmaceutical composition, care must be taken to ensure that the corresponding partners of the acid-base reaction are pharmaceutically acceptable, that is to say essentially non-toxic to humans in the amounts used.
  • the compounds are to be used as ⁇ -receptor ligands in in vitro reactions, compatibility is irrelevant, so that all acids or bases which are inert to the pharmaceuticals, apart from the protolysis reaction, are suitable as partners for the acid-base reaction behavior.
  • the substances to be used according to the invention form the active constituent of medicaments and medicaments which are used against cancer, that is to say in particular against carcinomas or sarcomas.
  • cancer that is to say in particular against carcinomas or sarcomas.
  • carcinomas in particular against carcinomas of the lungs, especially against small cell lung carcinomas and melanomas, is preferred.
  • the substances to be used according to the invention are generally administered in the dosage preferably between about 1 and 500 mg, in particular between 5 and 100 mg, per dosage unit.
  • the daily dosage is preferably between about 0.02 and 10 mg per kg of body weight.
  • the specific dose for each patient depends on a wide variety of factors, for example on the effectiveness of the particular compound used, on the age, body weight and general health, on sex, on the diet, on the time of administration and on the route of administration, on the rate of elimination , of the drug combination and the severity of the respective disease to which the therapy applies.
  • Oral application is preferred.
  • rectal application, parenteral application, in particular intravenous, intramuscular, and possibly intraperitoneal application are also possible.
  • the patient will be a mammal, with humans included.
  • the patient is an animal, including fish and birds. The invention is described in more detail by the following example.
  • the affinity of the substances to be used according to the invention on brain homogenate of guinea pigs was determined.
  • the affinity value is the IC- 50 value of the displacement of radioactively labeled SKF-10047 (in the case of the ⁇ i receptor) and of DTG (in the case of the ⁇ 2 receptor).
  • the affinity for the ⁇ i receptor was determined according to SW Tarn, European Journal of Pharmacology 1985, 109 (1), pages 33-41. Y. Shirayama et al., European Journal Pharmacology, 1993, 237 (1), pages 1 17-126 was used to determine the affinity for the ⁇ 2 receptor. The results are shown below.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation d'un composé choisi parmi 3-[4-(4-phényl-1,2-3,6-tétrahydro-1-pyridyl)-butyl]-indol-5-ole, 1-(2-(bis-(4-fluorophényl)méthoxy)éthyl)-4-(3-phényl-propyl)pipérazine, 1-(4-hydroxyphényl)-2-(4-benzyl-1-pipéridinyl)-propanol, 3-(4-((3S)-3-benzyl-1-pipéridyl)-butyl)-indol-5-carbonitrile, 3-(4-((3R)-3-benzyl-1-pipéridyl)-butyl)-indol-5-carbonitrile, 6-(4-(4-(5-fluoro-3-indolyl)-butyl)-1-pipérazinyl)-2H-1-benzopyran-2-one, (5S)-(-)-5-[4-(4-aminobenzyl)-1-pipéridylméthyl]-3-(4-éthylphényl)-oxazolidin-2-one, 6-{3-[4-(2,4-difluorobenzyl)-1-pipéridyl]-1-oxopropyl}-2,3-dihydrobenzoxazol-2-one, 3-(4-(3-(4-fluorophényl-hydroxyméthyl)pipérid-1-yl)butyl)-5-indolcarbonitrile, 2-(4-[3-(5H-dibenz[b,f]azépin-5-yl)-propyl]-1-pipérazinyl)-éthanol, 1-[2-(3,4-diméthoxyphényl)-éthyl]-4-(3-phénylpropyl)-pipérazine, (5S)-(-)-5-(4-benzyl-1-pipéridylméthyl)-3-(4-chlorophényl)-oxazolidin-2-one, 6-{3-[4-(4-fluorobenzyl)-1-pipéridyl]-2-méthylpropionyl}-2,3-dihydrobenzoxazol-2-one, (1R,2S)-(+)-4-(3-(4-benzyl-pipéridin-1-yl)-1-hydroxy-2-méthyl-propyl)-phénol, (E)-4-(3-(4-benzyl-pipéridin-1-yl)-2-méthyl-propényl)-phénol, 3-(4-(4-(2,1,3-benzothiadiazol-5-yl)-1-pipérazinyl)-butyl)-indol-5-carbonitrile, 6-(3-(4-(4-fluorobenzyl)-1-pipéridyl)-2-propényl)-2,3-dihydrobenzoxazol-2-one, 3-(4-trifluorométhylphénoxyméthyl)-pyrrolidine, 6-{3-[4-(4-fluorobenzyl)-1-pipéridyl]-propionyl}-3H-benzothiazol-2-one, 4-{3-[4-(4-fluorobenzyl)-pipéridin-1-yl]-propoxy}-phénol, [2-(4-méthoxy-3-phénéthyloxy-phényl)-éthyl]-dipropyl-amin, (1S,5R)-3-(2-(2-adamantyl)éthyl)-1,8,8-triméthyl-3-azabicyclo[3.2.1]octane, 6-{3-[4-(2,4-difluorobenzyl)-pipéridin-1-yl]-propionyl}-3H-benzothiazol-2-one, 1-{1-[2-(4-fluoro-phényl)-éthyl]-pipéridin-4-yl}-indan-1-ole, 1-[2-(4-fluoro-phényl)-éthyl]-4-(naphthalin-2-sulfinyl)-pipéridine, 1-(indol-4-yl)-4-[4-(4-fluorophényl)-butyl]-pipérazine, 3-(4-(2-(2-phényl-éthyl)-1-pipéridyl-1-butyl)-indole, 2-[4-(4-(3-indolyl)-butyl)-1-pipérazinyl]-benzonitrile, (S)-(-)-5-[4-hydroxy-4-(3,4-méthylendioxyphényl)-pipéridin-1-ylméthyl]-3-(4-méthoxyphényl)-oxazolidin-2-one, 5-fluoro-3-[4-phényl-1-pipéridyl)-butyl]-indole, 3-(1-phénéthyl-1,2,3,6-tétrahydro-4-pyridyl)-indol-5-carbonitrile, 3-(2-phényléthyl)-1,2,3,4,5,6-hexahydrobenz[f]isochinoline, 5-fluoro-3-(1-phénéthyl-4-pipéridyl)-indole, N-(1-benzyl-4-pipéridyl)-6-fluoro-1,2,3,4-tétrahydrocarbazol-3-carboxamide, 3-(4-(4-(4-cyanophényl)-1-pipérazinyl)-butyl)-indol-5-carbonitrile, 3-(3-(4-(2-carbamoyl-5-benzofuranyl)-1-pipérazinyl)-propyl)-indol-5-carbonitrile, 3-(4-(4-(4-fluorophényl)-1-pipérazinyl)-butyl)-indol-5-carbonitrile, 3-(4-(4-(2-cyanophényl)-pipérazinyl)-butyl)-indol-5-carbonitrile, 5-[3-[4-(-fluorobenzyl)-1-pipéridyl)-1-oxopropyl]-6-fluoro-2,3-dihydro-1H-benzimidazol-2-one, 6-(3-[4-(4-fluorobenzyl)-1-pipéridyl]-1-oxopropyl)-2,3-dihydrobenzoxazol-2-one, 3-(4-benzyl-1-pipéridyl)-1-(4-hydroxyphényl)-1-propanone, 3-(4-(4-(4-fluorophényl)-1-pipérazinyl)-butyl)indol-5-carbonitrile, 6-(3-[4-(4-fluorobenzyl)-1-pipéridyl]-1-hydroxypropyl)-2,3-dihydrobenzoxazol-2-one, 1-2(2-méthoxyphényl)-4-(2-(6,7,8,9-tétrahydro-5H-benzocyclohepten-6-yliden)-éthyl)-pipérazine, 3-(1-(2-(4-fluorophénoxy)-éthyl)-4-pipéridyl)-4,5-dihydro-2H-benz[g]indazole, (5S)-(-)-5-(4-(4-fluorobenzyl)-1-pipéridylméthyl)-3-(4-fluorophényl)-oxazolidin-2-one, 3-(4-((3R)-3-benzyl-1-pipéridyl)-butyl)-5-fluoroindole, 3-(4-((3S)-3-benzyl-1-pipéridyl)-butyl)-5-fluoroindole ou les acides, bases ou sels correspondants, qui servent de ligands de récepteur σ et/ou qui servent à combattre les carcinomes ou les sarcomes.
PCT/EP2001/011710 2000-10-11 2001-10-11 Utilisation de substances definies se liant aux recepteurs sigma dans le traitement de sarcomes et de carcinomes WO2002030422A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002210527A AU2002210527A1 (en) 2000-10-11 2001-10-11 Use of defined substances that bind to the sigma receptor for combating sarcoma and carcinoma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10050236A DE10050236A1 (de) 2000-10-11 2000-10-11 Verwendung bestimmter Substanzen, die an den Sigma-Rezeptor binden, zur Behandlung von Sarkomen und Karzinomen
DE10050236.9 2000-10-11

Publications (1)

Publication Number Publication Date
WO2002030422A1 true WO2002030422A1 (fr) 2002-04-18

Family

ID=7659331

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/011710 WO2002030422A1 (fr) 2000-10-11 2001-10-11 Utilisation de substances definies se liant aux recepteurs sigma dans le traitement de sarcomes et de carcinomes

Country Status (4)

Country Link
AR (1) AR031725A1 (fr)
AU (1) AU2002210527A1 (fr)
DE (1) DE10050236A1 (fr)
WO (1) WO2002030422A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070197594A1 (en) * 2004-09-21 2007-08-23 Astellas Pharma Inc. Cyclic amine derivative or salt thereof
EP1945213A2 (fr) * 2005-10-24 2008-07-23 Janssen Pharmaceutica N.V. Modulateurs du recepteur de r3-piperidine-4-yl-indole orl-1
WO2009046841A2 (fr) 2007-10-05 2009-04-16 Merck Patent Gmbh Dérivés de pipéridine et de pipérazine
US7786140B2 (en) * 2003-09-25 2010-08-31 Shionogi & Co., Ltd. Piperidine derivative having NMDA receptor antagonistic activity
WO2010112116A1 (fr) * 2009-04-02 2010-10-07 Merck Patent Gmbh Composés hétérocycliques comme inhibiteurs de l'autotaxine
WO2011044978A1 (fr) 2009-10-13 2011-04-21 Merck Patent Gmbh Dérivés d'oxyde sulfonique pour le traitement de tumeurs
CN105434438A (zh) * 2015-12-09 2016-03-30 昆明医科大学 一种伐诺司林二盐酸盐的药物新用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232931A (en) * 1990-05-29 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung Oxazolidinones
FR2688504A1 (fr) * 1992-03-13 1993-09-17 Synthelabo Derives de 2-(piperidin-1-yl)ethanol, leur preparation et leur application en therapeutique.
FR2717806A1 (fr) * 1994-03-22 1995-09-29 Adir Nouvelle aminoalkyl benzothiazolinones, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
EP0711763A1 (fr) * 1993-07-28 1996-05-15 Santen Pharmaceutical Co., Ltd. Nouveau derive de 1,4-di(phenylalkyl)piperazine
WO1998057953A1 (fr) * 1997-06-18 1998-12-23 Merck Patent Gmbh 3-benzylpiperidines

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232931A (en) * 1990-05-29 1993-08-03 Merck Patent Gesellschaft Mit Beschrankter Haftung Oxazolidinones
FR2688504A1 (fr) * 1992-03-13 1993-09-17 Synthelabo Derives de 2-(piperidin-1-yl)ethanol, leur preparation et leur application en therapeutique.
EP0711763A1 (fr) * 1993-07-28 1996-05-15 Santen Pharmaceutical Co., Ltd. Nouveau derive de 1,4-di(phenylalkyl)piperazine
FR2717806A1 (fr) * 1994-03-22 1995-09-29 Adir Nouvelle aminoalkyl benzothiazolinones, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
WO1998057953A1 (fr) * 1997-06-18 1998-12-23 Merck Patent Gmbh 3-benzylpiperidines

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BEART P M ET AL: "HETEROCYCLIC AMINO ALCOHOLS RELATED TO IFENPRODIL AS O RECEPTOR LIGANDS: BINDING AND CONFORMATIONAL ANALYSES", EUROPEAN JOURNAL OF PHARMACOLOGY. MOLECULAR PHARMACOLOGY SECTION, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 269, no. 2, 1994, pages 193 - 200, XP000601476, ISSN: 0922-4106 *
BRENT P J ET AL: "SIGMA BINDING SITE LIGANDS INHIBIT CELL PROLIFERATION IN MAMMARY AND COLON CARCINOMA CELL LINES AND MELANOMA CELLS IN CULTURE", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 278, no. 2, 15 May 1995 (1995-05-15), pages 151 - 160, XP000645467, ISSN: 0014-2999 *
HUSBANDS STEPHEN M ET AL: "Structure-activity relationships at the monoamine transporters and sigma receptors for a novel series of 9-(3-(cis-3,5-dimethyl-1-pipera zinyl)-propyl)carbazole (rimcazole) analogues.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 42, no. 21, October 1999 (1999-10-01), pages 4446 - 4455, XP001026440, ISSN: 0022-2623 *
MAJ, JERZY ET AL: "Some behavioral effects of 1,3-di-O-tolylguanidine, opipramol and sertraline, the sigma site ligands", POL. J. PHARMACOL. (1996), 48(4), 379-395, XP002190536 *
PERREGAARD J ET AL: "Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H- indoles.", JOURNAL OF MEDICINAL CHEMISTRY, (1995 MAY 26) 38 (11) 1998-2008., XP000941460 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7786140B2 (en) * 2003-09-25 2010-08-31 Shionogi & Co., Ltd. Piperidine derivative having NMDA receptor antagonistic activity
US20070197594A1 (en) * 2004-09-21 2007-08-23 Astellas Pharma Inc. Cyclic amine derivative or salt thereof
EP1945213A4 (fr) * 2005-10-24 2009-12-02 Janssen Pharmaceutica Nv Modulateurs du recepteur de r3-piperidine-4-yl-indole orl-1
EP1945213A2 (fr) * 2005-10-24 2008-07-23 Janssen Pharmaceutica N.V. Modulateurs du recepteur de r3-piperidine-4-yl-indole orl-1
AU2008310067B2 (en) * 2007-10-05 2013-09-26 Merck Patent Gmbh Piperidine and piperazine derivatives for treating tumours
EA017787B1 (ru) * 2007-10-05 2013-03-29 Мерк Патент Гмбх Производные пиперазина
DE102007047737A1 (de) 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
US8791111B2 (en) 2007-10-05 2014-07-29 Merck Patent Gmbh Piperidine and piperazine derivatives
JP2010540579A (ja) * 2007-10-05 2010-12-24 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 腫瘍の治療のためのピペリジンおよびピペラジン誘導体
JP2014129427A (ja) * 2007-10-05 2014-07-10 Merck Patent Gmbh 腫瘍の治療のためのピペリジンおよびピペラジン誘導体
US8754097B2 (en) 2007-10-05 2014-06-17 Merck Patent Gmbh Piperidine and piperazine derivatives
WO2009046841A2 (fr) 2007-10-05 2009-04-16 Merck Patent Gmbh Dérivés de pipéridine et de pipérazine
EP2426106A1 (fr) 2007-10-05 2012-03-07 Merck Patent GmbH Dérivés de pipéridine et de pipérazine pour le traitement des tumeurs
WO2009046841A3 (fr) * 2007-10-05 2009-06-18 Merck Patent Gmbh Dérivés de pipéridine et de pipérazine
JP2012522733A (ja) * 2009-04-02 2012-09-27 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング オートタキシン阻害剤としての複素環式化合物
CN102365271A (zh) * 2009-04-02 2012-02-29 默克专利有限公司 作为自分泌运动因子抑制剂的杂环化合物
WO2010112116A1 (fr) * 2009-04-02 2010-10-07 Merck Patent Gmbh Composés hétérocycliques comme inhibiteurs de l'autotaxine
US8841324B2 (en) 2009-04-02 2014-09-23 Merck Patent Gmbh Heterocyclic compounds as autotaxin inhibitors
DE102009049211A1 (de) 2009-10-13 2011-04-28 Merck Patent Gmbh Sulfoxide
WO2011044978A1 (fr) 2009-10-13 2011-04-21 Merck Patent Gmbh Dérivés d'oxyde sulfonique pour le traitement de tumeurs
CN105434438A (zh) * 2015-12-09 2016-03-30 昆明医科大学 一种伐诺司林二盐酸盐的药物新用途
CN105434438B (zh) * 2015-12-09 2019-09-17 昆明医科大学 一种伐诺司林二盐酸盐的药物用途

Also Published As

Publication number Publication date
AU2002210527A1 (en) 2002-04-22
AR031725A1 (es) 2003-10-01
DE10050236A1 (de) 2002-04-25

Similar Documents

Publication Publication Date Title
DE69925730T2 (de) 4-benzyl-piperidin-alkylsulfoxid-heterozyklen und ihre verwendung als subtyp-selektive nmda rezeptor antagonisten
DE2941880C2 (fr)
DE69636877T2 (de) Optisch reines (-) norcisaprid zur Behandlung von Krankheiten des Verdauungstraktes
DE69922186T2 (de) 1-(1-subst.-4-piperidinyl)methyl]-4-piperidin-derivate, verafhren zu deren herstellung, pharmazeutische mixturen und intermediate zu deren herstellung
DE69924375T2 (de) Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms
DE60106287T2 (de) Chemische verbindungen
DE602004009426T2 (de) Kalziumkanalblocker mit zwei benzhydril-teilen
DD292909A5 (de) Verfahren zur herstellung neuer 2-(1-piperazinyl)-4-phenylcycloalkanopyridinderivate
DE60022867T2 (de) 1-Arenesulfonyl-2-Aryl-Pyrrolidin und Piperidin Derivative zur Behandlung von CNS-Erkrankungen
DE69326650T2 (de) Piperidinderivate von Benzimidazole als antihistaminische und antiallergische Mittel
DE69430816T2 (de) Verwendung von Piperidin-Derivaten in der Behandlung von Schizophrenie
CN102369186A (zh) 作为自分泌运动因子抑制剂的哌啶和哌嗪衍生物
DE3507983A1 (de) 1-fluorphenylbutyl-4-(2-pyrimidinyl)-piperazin-verbindungen, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische mittel
DE60210581T2 (de) Substituierte carbostyrilderivate als 5-ht1a-subtyp agonisten
KR910019617A (ko) 뇌 및 신경질환 치료용 약제의 제조를 위한 1-(2-나프틸에틸)-4-(3-트리플루오로메틸페닐)-1,2,3,6- 테트라히드로피리딘의 용도
DE69903239T2 (de) Auf serotonin-verwandte Systeme wirkende Piperidin-Derivate
DE69819903T2 (de) Bicyclische verbindungen als liganden der 5-ht1 rezeptoren
DE69105135T2 (de) Piperidyl-substituierte indole.
EP1833478A1 (fr) Utilisation d'antagonistes selectionnes du cgrp en association avec d'autres substances medicinales contre la migraine, pour traiter la migraine
WO2002030422A1 (fr) Utilisation de substances definies se liant aux recepteurs sigma dans le traitement de sarcomes et de carcinomes
CN103108548A (zh) 使用环酰胺衍生物治疗σ受体介导的病症的方法
CN101328151A (zh) 苯并咪唑衍生物、含有它们的组合物、它们的制备以及它们的用途
KR20050072794A (ko) 4(페닐-피페라지닐-메틸)벤즈아미드 유도체 및 통증 또는위장 장애 치료에 있어서의 그의 용도
DD290884A5 (de) Verfahren zur herstellung von pyridyl- und pyrimidylderivaten
DE69924488T2 (de) Verwendung von optisch reinem (-) norcisapride in der behandlung des reizdarmsyndroms

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP